Redefining the treatment 
of hematologic diseases

PharmaEssentia is a fully integrated, global biopharmaceutical company working to bring new, best-in-class therapies to patients with blood disorders and cancers.

Discover More

  • Jan 30, 2026

    Professional Article

    Essential Thrombocythemia vs Polycythemia Vera: Understanding MPNs

    Learn More

  • Jan 23, 2026

    Newsroom

    The U.S. NCCN Guidelines Included Ropeginterferon alfa-2b-njft (P1101) as a Recommended Treatment Option for Patients with Essential Thrombocythemia (ET)

    Learn More

We've redesigned interferons

See how we're introducing innovative options for more patients.

Explore Our Solutions

Better science leads to better lives

Learn how we're expanding options for patients with rare blood cancers.

Discover More

Changing what's possible for people with rare cancers

At PharmaEssentia, we discover new treatments and deliver improvements to as many people as possible.

Welcome to PharmaEssentia Medical Affairs

Your source for educational, clinical, and scientific information about PharmaEssentia programs to address unmet medical needs in hematologic oncology and other cancers.

Learn More

Investors

  • Financial Information
    • Monthly Revenue
    • Financial Report
    Learn More
    • Shareholder’s Services
      • Shareholder's Meeting
      • 2025 Annual General Meeting
      • Announcement Inquiry
      • Stock Price
      Learn More
      • Events & Presentations
        Learn More

      Join our team

      Want to make a positive impact on the lives of others, while expanding your own possibilities?

      Learn More